Inflammatory activity and anticardiolipin antibodies during tibolone treatment of healthy postmenopausal women.
The aim of the study was to investigate the inflammatory activity and anticardiolipin antibodies (Acl) during tibolone administration. Twenty seven clinically healthy postmenopausal women were included in the study and were divided into two groups: 16 women (mean age 56.4 +/- 4.6 years) who received tibolone at a dose of 2.5 mg/day for 6 months and an untreated control group (n = 11, mean age 54.8 +/- 4.0 years). Acl of IgG and IgM isotype, and C-reactive protein (CRP) were determined at baseline, 1, 3, and 6 months after treatment. Acl did not change during tibolone treatment, while CRP increased significantly at the 1st, 3rd, and 6th month compared with that at the baseline values. These preliminary data indicate that tibolone administration does not induce increase in Acl. This may counterbalance the adverse influence on CRP.
Todorova
M
M
Department of Pathophysiology, Alexandrov's Hospital, Medical University, Sofia, Bulgaria. todorovamariabg@yahoo.com
Kamenov
Z
Z
Christov
V
V
Baleva
M
M
D017153:Antibodies, Anticardiolipin / Q000097:blood; D002097:C-Reactive Protein / Q000096:biosynthesis / Q000187:drug effects*; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000276:immunology*; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage*; D017698:Postmenopause / Q000097:blood*; D013997:Time Factors; D015854:Up-Regulation
D017153:Antibodies, Anticardiolipin; D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; D002097:C-Reactive Protein; C027385:tibolone